Nuformix plc

LVRT

GB00BYW79Y38

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:24 2024-07-03 EDT			5-day change	1st Jan Change
0.175 ^GBX	0.00%		+2.94%	-46.15%

06-18	Nuformix shares fall despite interim loss narrowing	AN
06-18	Nuformix plc Reports Earnings Results for the Half Year Ended March 31, 2024	CI

Nuformix plc Appoints Anne Brindley as Chief Executive Officer

December 07, 2020 at 02:00 am

Nuformix plc announced the appointment of Dr. Anne Brindley as Chief Executive Officer with immediate effect. Anne was previously CEO of Advent Pharmaceuticals Pty Ltd. In that role, Anne led a successful sale of the products and assets to AuroScience Pty Ltd. She subsequently became CEO of AuroScience Pty Ltd.

Latest news about Nuformix plc

Nuformix shares fall despite interim loss narrowing	06-18	AN
Nuformix plc Reports Earnings Results for the Half Year Ended March 31, 2024	06-18	CI
Nuformix Secures New EU, US Patents for Development Programs	06-17	MT
Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment	06-17	AN
Nuformix plc Announces Patent Update	06-17	CI
Nuformix announces subscription to raise GBP150,000	03-01	AN
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	01-15	CI
Nuformix narrows annual loss as develops drug assets	01-03	AN
Earnings Flash (NFX.L) NUFORMIX Reports FY23 Loss GBX-0.12	01-03	MT
Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023	01-03	CI
Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002	23-10-23	AN
Nuformix Receives Japanese Patent for Pulmonary Fibrosis Treatment; Shares Surge	23-10-23	MT
Nuformix plc Announces Notice of Allowance of NXP002 Patent in Japan	23-10-23	CI
Nuformix Updates Oxilio Agreement for NXP001	23-09-18	MT
Nuformix to receive milestone payments from Oxilio pact	23-09-18	AN
Nuformix plc Receives New NXP001 Development Milestone Payments in Updated Oxilio Agreement	23-09-18	CI
Nuformix loss narrows; near-term goal to focus on NXP002 asset	23-05-22	AN
Earnings Flash (NFX.L) NUFORMIX Posts FY23 EPS GBX0.11	23-05-22	MT
Earnings Flash (NFX.L) NUFORMIX Posts Fiscal H1 EPS GBX0.11	23-05-22	MT
Nuformix plc Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-22	CI
Nuformix says NXP002 shows anti-inflammatory effect	23-05-18	AN
Nuformix to Launch Partnering Process for Inhaled Lung Disease Drug	23-05-18	MT
Nuformix plc Announces Update Regarding the NXP002 Programme	23-05-18	CI
FTSE 100 Inches Up as Market Awaits Key Inflation, Earnings Figures	23-04-17	DJ
UK Inflation Likely Dropped Below Double Digits in March	23-04-17	DJ

Chart Nuformix plc

Duration

Period

More charts

Company Profile

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NUFORMIX PLC	-46.15%	1.82M
ELI LILLY AND COMPANY	+54.07%	816B
NOVO NORDISK A/S	+38.59%	634B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	323B
ABBVIE INC.	+5.72%	293B
ASTRAZENECA PLC	+13.40%	238B
ROCHE HOLDING AG	+0.61%	222B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	167B

Other Pharmaceuticals

Nuformix plc

Equities

LVRT

GB00BYW79Y38

Pharmaceuticals

Nuformix plc Appoints Anne Brindley as Chief Executive Officer

Latest news about Nuformix plc

Chart Nuformix plc

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals